iShares Genomics Immunology and Healthcare
ALTAR
Score™
-4.8% info Recommen-
dation
AVOID
2019E    2020E
P/E
ratio
-22.8x P/Sales
ratio
7.3x
P/BV
ratio
4.4x Div.
yield
0.8%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
IDNA seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

FUND BASICS
Category Global Equities
Fund Sponsor Blackrock
Website www.ishares.com
Inception date Jun 11, 2019
Assets (mns) $24
Currency USD
Expense ratio 47 bp
Distributions Annually

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian
Weighting Market Value
Index replication
Uses derivatives No
Options available Yes

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 44
Wgt avg mkt cap (mns) $24,725
Large cap (>$10bn) 33.9%
Mid cap ($2-10bn) 36.2%
Small cap (<$2bn) 29.9%
Developed mkts 100.0%
Emerging mkts 0.0%

TOP TEN HOLDINGS
SEATTLE GENETICS INC 6.6 %
ALNYLAM PHARMACEUTICALS INC 5.3 %
GENMAB A/S 5.2 %
REGENERON PHARMACEUTICALS 4.6 %
SPARK THERAPEUTICS, INC. 4.1 %
MIRATI THERAPEUTICS INC 3.9 %
BRISTOL-MYERS SQUIBB CO 3.8 %
ASTRAZENECA PLC 3.8 %
FIBROGEN INC 3.8 %
TAKEDA PHARMACEUTICAL CO LTD 3.7 %
Total 44.8 %

TOP COUNTRY EXPOSURE
UNITED STATES 72.5 %
JAPAN 7.2 %
SWITZERLAND 5.2 %
DENMARK 5.2 %
BRITAIN 3.8 %
FRANCE 3.2 %
GERMANY 2.6 %




HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru January 01)
Year-to-date 1 year 5 years 10 years Since Incep.
-- -- -- -- 0.0%

Market Correlations
versus... Beta R-squared
S&P500 -- --
MSCI EAFE -- --
MSCI Emg. Mkts. -- --

Technical Indicators
Recent close $27.04
30d moving avg. $25.60
Annualized volatility 0.0%
Short interest (ETF) 0.1%
Relative strength (RSI) 70

Liquidity measures
Avg. volume (thou.) 1
Turnover 0.1%
Bid/Ask (% of price) 0.16%
ADV underlying (mns) $3,427

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the iShares Genomics Immunology and Healthcare ETF based on the alternatives' overlap in portfolio holdings with IDNA. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: IDNA Expense: 47 bp ALTAR Score™: -4.8%


ALTERNATIVE ETFs BASED ON OVERLAP WITH IDNA
Ticker Fund
Name
Overlap1
vs IDNA
(%)
Expense
ratio
(bp)
Savings
vs IDNA
(bp)
ALTAR
Score™
(%)
ALTAR
vs IDNA
(%)
CNCR Loncar Cancer Immunotherapy 29.1 79 -32 -3.8 +1.0
XBI SPDR S&P Biotech ETF 26.4 35 12 -5.0 -0.2
GNOM Global X Genomics & Biotechnology 24.4 68 -21 -6.4 -1.6
FBT First Trust NYSE-ARCA Biotechnology 22.4 57 -10 -0.8 +4.0
BTEC Principal Healthcare Innovators Index 21.9 42 5 -4.5 +0.3
GDNA Goldman Sachs Motif Human Evolution 21.2 50 -3 1.0 +5.8
BBP BioShares Biotech Products 18.3 79 -32 -3.9 +0.9
SBIO ALPS Medical Breakthroughs 17.3 50 -3 -6.1 -1.4
ARKG ARK Genomic Revolution Multi-Sector 15.8 75 -28 -4.2 +0.6
BBC Virtus LifeSci Biotech Clinical Trials 15.7 79 -32 -14.3 -9.5
IBB iShares NASDAQ Biotechnology 15.2 47 0 1.3 +6.1
BBH VanEck Vectors Biotech 13.1 35 12 5.4 +10.1
IEIH iShares Evolved U.S. Innovative Healthcare 12.2 18 29 4.8 +9.6
IXJ iShares S&P Global Healthcare 11.4 46 1 6.5 +11.2
LNGR Global X Longevity Thematic 9.6 50 -3 3.6 +8.4
FXH First Trust Health Care Alphadex 8.3 63 -16 7.2 +12.0
ARKK ARK Innovation 7.5 75 -28 -4.7 +0.1
HDEF Xtrackers MSCI EAFE High Div Yld Hedged 7.0 20 27 8.5 +13.3
PBE Invesco Dynamic Biotechnology & Genome 6.8 57 -10 0.0 +4.8
PJP Invesco Dynamic Pharmaceuticals 6.0 56 -9 9.8 +14.5

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
iShares Genomics Immunology and Healthcare
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity -23.4 %
Divided by: Fwd. P/BV 5.4 x
Less: Expense ratio 47 bp
Equals: ALTAR Score -4.8 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.36 CATEGORY
AVERAGE
1.54
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.